-transparent.png){kind=logo}
A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients. Data on 9,037 patients were collected by 1,455 participating physicians. Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol-hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and weakness. Treatment in 590 patients was discontinued because of adverse events.
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
April 1983,
Journal of clinical pharmacology,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
September 1981,
La Clinica terapeutica,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
February 1981,
Annals of clinical research,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
August 1981,
American journal of hospital pharmacy,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
March 1983,
Fortschritte der Medizin,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
January 1976,
Duodecim; laaketieteellinen aikakauskirja,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
July 1964,
Clinical medicine (Northfield, Ill.),
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
March 1978,
L'union medicale du Canada,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
February 1986,
The American journal of medicine,
J A Bannon, and
K A Stewart, and
J J Schrogie, and
O Delisser
June 1984,
The American journal of cardiology,
